Trial reportAntimicrobial agents and chemotherapy2013
Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis.
Trial report in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- An Overview of the Treatment of Onychomycosis in Patients with Diabetes: Current Pharmacological and Non-Pharmacological Options.Clinical, cosmetic and investigational dermatology · 2026Review
- Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics.The Journal of clinical and aesthetic dermatology · 2024Review
- Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.Infection and drug resistance · 2024Review
- Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.Mycoses · 2022Article
- Formulation and Development of a Water-in-Oil Emulsion-Based Luliconazole Cream:International journal of analytical chemistry · 2022Article
- Luliconazole, a highly effective imidazole, against Fusarium species complexes.Medical microbiology and immunology · 2020Article
- ONYCHOMYCOSIS: A Review of New and Emerging Topical and Device-based Treatments.The Journal of clinical and aesthetic dermatology · 2019Review
- Molecular Docking-Guided Ungual Drug-Delivery Design for Amelioration of Onychomycosis.ACS omega · 2019Article
- LowAntimicrobial agents and chemotherapy · 2018Article
- Therapy of Skin, Hair and Nail Fungal Infections.Journal of fungi (Basel, Switzerland) · 2018Review
- Onychomycosis: A Review.Journal of fungi (Basel, Switzerland) · 2015Review
- Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.Antimicrobial agents and chemotherapy · 2014Article
- Luliconazole for the treatment of fungal infections: an evidence-based review.Core evidence · 2014Review
- Newer Topical Treatments in Skin and Nail Dermatophyte Infections.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study objective was to evaluate the safety, tolerability, systemic exposure, and pharmacokinetics (PK) of 10% luliconazole solution (luliconazole) when topically applied once daily to all 10 toenails and periungual areas in patients with moderate to severe distal subungual onychomycosis. In this single-center, open-label study, 24 patients applied 20 mg/ml of luliconazole (twice the clinical dose) for 29 days with a 7-day follow-up. Complete PK profiles were determined on days 1, 8, 15, and 29. Safety/tolerability assessments included application site reactions, adverse events, vital signs, clinical laboratory findings, and electrocardiograms. Mean luliconazole plasma concentrations remained around the lower limit of quantitation (0.05 ng/ml) and were comparable on days 8, 15, and 29 (range, 0.063 to 0.090 ng/ml), suggesting steady state occurred by day 8. Every patient had undetectable plasma luliconazole levels for at least 11% of the time points, and 12 of the 24 patients had undetectable levels for at least 70% of the time points. The maximum plasma concentration of luliconazole (C(max)) observed in any patient was 0.314 ng/ml and the maximum area under the concentration-time curve from 0 to 24 h (AUC0-24) was 4.34 ng · h/ml. Five patients (21%) had measureable luliconazole levels in the plasma 7 days after the last dose. The median concentration of luliconazole in the nail at this time point was 34.65 mg/g (from 42 of 48 collected toenail samples). There was one mild incidence of skin erythema on day 5 that resolved on day 8, there were no reports of drug-induced systemic side effects, and there was no evidence of QT prolongation. Luliconazole, when applied once daily to all 10 fungus-infected toenails for 29 days, is generally safe and well tolerated and results in significant accumulation of drug in the nail. Systemic exposure is very low, with no evidence of drug accumulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.